234082-22-5

Basic information

• Product Name: 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid
• Synonyms: 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid
• CAS NO: 234082-22-5
• Molecular Weight: 329.315
• Mol File: 234082-22-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid(234082-22-5)
• EPA Substance Registry System: 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid(234082-22-5)

Safety Data

• Hazardous Substances Data: 234082-22-5(Hazardous Substances Data)

Upstream product

• 157160-99-1 4-Chloro-3-nitrobenzoic acid tert-butyl ester 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 94021-22-4 1-(2-pyrimidyl)piperazine dihydrochloride 

Downstream Products

• 234081-37-9 tert-butyl (2S)-benzenesulfonylamino-3-[3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoylamino]propionate 

Relevant articles and documents

Design, synthesis and antiviral activity of 2-(3-amino-4-piperazinylphenyl) chromone derivatives

Previously, we have confirmed that the antiviral activities of the chromone derivatives were controlled by the type as well as the position of the substituents attached to the chromone core structure. In the course of our ongoing efforts to optimize the antiviral activity of the chromone derivatives, we have been attempting to derivatize the chromone scaffold via introduction of various substituents. In this proof-of-concept study, we introduced a 3-amino-4-piperazinylphenyl functionality to the chromone scaffold and evaluated the antiviral activities of the resulting chromone derivatives. The synthesized 2-(3-amino-4-piperazinylphenyl)- chromones showed severe acute respiratory syndrome-corona virus (SARS-CoV)-specific antiviral activity. In particular, the 2-pyridinylpiperazinylphenyl substituents provided the resulting chromone derivatives with selective antiviral activity. Taken together, this result indicates the possible pharmacophoric role of the 2-pyridinylpiperazine functionality attached to the chromone scaffold, which warrants further in-depth structure-activity relationship study.

Phenylpiperazine derivatives as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin αvβ3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.